Efficacy of Selective Laser Trabeculoplasty in Patients on Systemic Immunosuppressive Therapy.
Efficacy of Selective Laser Trabeculoplasty in Patients on Systemic Immunosuppressive Therapy.
复制标题
选择性激光小梁成形术对接受全身免疫抑制治疗的患者的疗效。
DOI：
10.1097/ijg.0000000000002259
复制
发表时间：
2023
影响因子：
2
通讯作者：
Roddy,GavinW
中科院分区：
文献类型：
--
作者：
Kaplan,TylerM;Hammer,JonD;Kohli,Darrel;Pacheco,JohannM;Hodge,DavidO;Khanna,CherylL;Sit,ArthurJ;Roddy,GavinW
目的：确定与对照组患者相比，服用全身免疫抑制药物的患者对选择性激光小梁成形术（LASIK）的降眼压反应是否不同。方法：确定了2017-2021年在马约诊所接受LASIK的所有患者。将接受全身免疫抑制药物治疗的患者与未接受全身免疫抑制药物治疗的对照组患者进行比较。本研究的主要终点是1至2个月、3至6个月和12个月时的IOP降低百分比。额外的分析包括谁不需要额外的治疗，在每个时间点的患者的百分比。结果：有108眼的72例患者进行了免疫抑制组和1997眼的1417例患者在对照组。两组在术后1 - 2个月（− 18.8±20.7% vs.− 16.0± 16.5%，P= 0.256）或术后3-6个月（− 15.2±21.6% vs.− 18.3± 23.2%，P= 0.062）的首次术后访视时，年龄调整后的IOP变化无显著差异。然而，在眼内直视术后12个月，免疫抑制治疗组的IOP降低程度显著低于对照组（− 15.1±21.2% vs.− 20.3± 22.9%，P= 0.045）。两组之间没有差异的额外治疗的数量在studyintervation.Conclusion：在全身免疫抑制治疗组的患者表现出等效的早期IOP降低后，与对照组相比，眼内直视手术，但治疗反应减少了1年。需要进一步研究免疫抑制患者眼内压的调节。
Purpose:To determine whether patients taking systemic immunosuppressive medications have a different IOP-lowering response to selective laser trabeculoplasty (SLT) compared with a control group of patients.Methods:All patients who underwent SLT at Mayo Clinic 2017–2021 were identified. Patients on systemic immunosuppressive medications at the time of SLT were compared with control patients not receiving systemic immunosuppressive medications. The primary endpoints of this study were the percentage IOP reduction at 1 to 2, 3 to 6, and 12 months. Additional analyses included the percentage of patients who did not require additional therapy at each time point.Results:There were 108 eyes of 72 patients that underwent SLT in the immunosuppressed group and 1997 eyes of 1417 patients in the control group. There was no significant difference in age-adjusted change in IOP between groups at the first postoperative visit 1 to 2 months following SLT (− 18.8±20.7% vs.− 16.0±16.5%, P= 0.256) or 3–6 months following SLT (− 15.2±21.6% vs.− 18.3±23.2%, P= 0.062). However, at 12 months following SLT, the IOP reduction in the immunosuppressive therapy group was significantly less compared with the control group (− 15.1±21.2% vs.− 20.3±22.9%, P= 0.045). There was no difference between groups in the number of additional treatments during the study intervals.Conclusion:Patients in the systemic immunosuppressive therapy group showed equivalent early IOP-lowering after SLT compared with a control group, but the treatment response was diminished at 1 year. Further studies investigating IOP regulation after SLT in immunosuppressed patients are needed.